- Report
- April 2024
- 328 Pages
Global
From €5389EUR$5,885USD£4,350GBP
- Report
- March 2025
- 191 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- July 2024
- 144 Pages
Global
From €2843EUR$2,999USD£2,375GBP
- Report
- May 2024
- 201 Pages
Global
From €4734EUR$4,995USD£3,955GBP
- Report
- December 2022
- 226 Pages
Global
From €4549EUR$4,799USD£3,800GBP
- Report
- March 2022
- 933 Pages
Global
From €3071EUR$3,240USD£2,566GBP
€3412EUR$3,600USD£2,851GBP
- Report
- May 2022
- 225 Pages
Global
From €5260EUR$5,550USD£4,395GBP
- Report
- February 2018
- 15 Pages
Global
- Report
- April 2023
- 68 Pages
Australia
From €4502EUR$4,750USD£3,761GBP
- Report
- April 2023
- 75 Pages
United States
From €4502EUR$4,750USD£3,761GBP
- Report
- November 2021
- 747 Pages
Global
From €3791EUR$4,000USD£3,167GBP
- Book
- December 2013
- 550 Pages
- Book
- January 2015
- 360 Pages

The Oncology Drug Delivery market is a subset of the larger Drug Delivery market, which focuses on the development and delivery of drugs to treat cancer. This market is driven by the need to improve the efficacy of cancer treatments, as well as to reduce the side effects associated with them. Drug delivery systems are designed to target specific areas of the body, allowing for more precise delivery of the drug. This can help to reduce the amount of drug needed, as well as the amount of time it takes for the drug to reach its target.
The Oncology Drug Delivery market is highly competitive, with many companies offering innovative solutions to improve the delivery of cancer treatments. Companies such as Novartis, Merck, Pfizer, and Sanofi are all major players in this market, offering a range of drug delivery systems for cancer treatments. Other companies such as Amgen, Celgene, and Bristol-Myers Squibb are also active in this market, providing a range of drug delivery solutions for cancer treatments. Show Less Read more